Bio-Rad Laboratories BIO Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 51.9%0.0pp | 51.9%-0.4pp | 52.3%-0.6pp | 52.8%-0.7pp | 53.5%-0.2pp | |
| Net margin | 6.5%-22.9pp | 29.4%+55.8pp | -26.4%-38.9pp | 12.5%+97.7pp | -85.2%-13.3pp | |
| Free cash flow margin | 13.8%-0.7pp | 14.5%+1.3pp | 13.2%-1.4pp | 14.5%+0.5pp | 14%+2.7pp | |
| Returns | ||||||
| Return on equity | 2.5%-8.3pp | 10.8%+20.3pp | -9.5%-14.1pp | 4.6%+32.1pp | -27.5%-3.4pp | |
| Return on assets | 1.7%-5.9pp | 7.6%+14.3pp | -6.7%-9.9pp | 3.2%+22.8pp | -19.6%-2.5pp | |
| Return on invested capital | 11.4%+0.7pp | 10.7%+7.9pp | 2.8%+0.8pp | 2%-0.8pp | 2.8%-0.3pp | |
| Efficiency | ||||||
| Asset turnover | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | 0.2×0.0× | |
| Inventory turnover | 1.6×-0.1× | 1.7×+0.1× | 1.5×0.0× | 1.5×0.0× | 1.5×0.0× | |
| Liquidity | ||||||
| Current ratio | 3.2×-2.4× | 5.6×+0.2× | 5.4×+0.3× | 5.1×-0.9× | 6×-0.5× | |
| Quick ratio | 2.4×-1.8× | 4.2×+0.2× | 3.9×+0.3× | 3.7×-0.8× | 4.4×-0.4× | |
| Cash ratio | 0.6×-0.5× | 1×+0.3× | 0.8×+0.1× | 0.7×-0.4× | 1×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Interest coverage | 22.7×+0.1× | 22.6×+18.0× | 4.6×0.0× | 4.6×-0.5× | 5.1×-0.4× | |
| Per Share | ||||||
| Book value per share | $254.15-7.0% | $273.22+9.2% | $250.22-4.4% | $261.82+9.6% | $238.93+2.6% | |
| Valuation | ||||||
| Market capitalization | $7.52B-7.9% | $8.17B+7.7% | $7.59B+17.2% | $6.47B-5.1% | $6.82B-25.8% | |
| Enterprise value | $8B-11.4% | $9.03B+5.1% | $8.59B+14.3% | $7.52B-2.1% | $7.68B-23.9% | |
| Price / earnings | 44.6×+33.8× | 10.8×— | —— | 20.3×— | —— | |
| Price / sales | 2.9×-0.3× | 3.2×+0.2× | 3×+0.4× | 2.5×-0.2× | 2.7×-0.9× | |
| Price / book | 1.1×0.0× | 1.1×0.0× | 1.1×+0.2× | 0.9×-0.1× | 1×-0.4× | |
| EV / sales | 3.1×-0.4× | 3.5×+0.1× | 3.4×+0.4× | 2.9×-0.1× | 3×-0.9× | |
| Free cash flow yield | 4.7%+0.2pp | 4.6%+0.1pp | 4.4%-1.3pp | 5.7%+0.5pp | 5.2%+2.1pp | |
| Earnings yield | 2.2%-7.1pp | 9.3%+18.2pp | -8.9%-13.8pp | 4.9%+36.7pp | -31.7%-11.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Bio-Rad Laboratories's profit margins?
- Bio-Rad Laboratories (BIO) runs a 51.9% gross margin and a 8.8% operating margin, with a 6.5% net margin.
- Where do Bio-Rad Laboratories's ratios come from?
- Every ratio is computed from Bio-Rad Laboratories's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
